Skip to content
← Full study record

NCT00027560 · OUTCOME

Overall Survival

Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer · Source last updated 2013-01-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
12 months post transplant

Analysis population: Population is defined as all participants who received transplant as per protocol.

Groups in this outcome

TREATMENT OF LYMPHOHEMATOPOIETIC MALIGNANCIES

This is a stratified single-armed phase II study designed to investigate the safety and efficacy of hematopoietic cell allografts administered after nonmyeloablative cytoreduction.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
TREATMENT OF LYMPHOHEMATOPOIETIC MALIGNANCIES50

Reported measurements

Source class 1
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
TREATMENT OF LYMPHOHEMATOPOIETIC MALIGNANCIES37Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        37
denoms
  1. counts
    1. group Id
      OG000
      value
      50
    units
    Participants
groups
  1. description
    This is a stratified single-armed phase II study designed to investigate the safety and efficacy of hematopoietic cell allografts administered after nonmyeloablative cytoreduction.
    id
    OG000
    title
    TREATMENT OF LYMPHOHEMATOPOIETIC MALIGNANCIES
param Type
NUMBER
population Description
Population is defined as all participants who received transplant as per protocol.
reporting Status
POSTED
time Frame
12 months post transplant
title
Overall Survival
type
PRIMARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice